Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesTevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
6.0 USD 0.28 ( 4.90%)
Last update at 2026-11-11T21:00:00Z
VOLUME
2912
Market Cap
164.61M

Momentum Score

…

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
5.91
Low
6.00
High
52 Week Price Range
0.75
Low
21.09
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
5.72
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-
Net Debt
33.81M
ROCE
-0.27%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30
Type yearly yearly
Date 2023-06-30 2022-06-30
Income before tax 4.41M -15.60M
Net income 4.41M -15.60M
Selling general administrative 0.95M 1.66M
Reconciled depreciation 0.23M 0.01M
Operating income -0.95M -4.62M
Interest expense 0.00M 0.60M
Net interest income 0.00M -0.60M
Total revenue 0.00M 0.00M
Total operating expenses 0.95M 4.62M
Total other income expense net 5.36M -10.38M
Net income from continuing ops 4.41M -15.60M
Breakdown 2023-06-30 2022-06-30
Type yearly yearly
Date 2023-06-30 2022-06-30
Total assets 357.14M 7.66M
Other current assets 0.15M 0.05M
Total liab 15.06M 24.15M
Total stockholder equity 342.08M -16.49M
Other current liab 0.24M 0.05M
Capital stock 356.87M 0.06M
Retained earnings -14.78M -17.14M
Cash 0.13M 7.12M
Total current liabilities 0.35M 0.67M
Net debt 33.81M 16.36M
Total current assets 0.27M 7.17M
Long term debt 39.30M 23.48M
Accounts payable 0.21M 0.38M
Non currrent assets other 356.86M 0.34M
Non current assets total 356.86M 0.49M
Capital lease obligations 0.71M 0.00M
Breakdown 2023-06-30 2022-06-30
Type yearly yearly
Date 2023-06-30 2022-06-30
Investments -0.48M -0.11M
Total cash from financing activities 7.50M 12.50M
Net income -22.04M -15.60M
Change in cash -1.63M 7.12M
Begin period cash flow 7.12M 0.00M
End period cash flow 5.48M 7.12M
Total cash from operating activities -8.66M -5.27M
Depreciation 0.23M 0.01M
Sale purchase of stock 0.00M -
Capital expenditures 0.48M 0.11M
Change in working capital 0.26M -1.25M
Stock based compensation 4.58M 0.58M
Other non cash items 8.32M 10.98M
Free cash flow -9.13M -5.38M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
TVGN
Tevogen Bio Holdings Inc.		 0.28
4.90%		 6.00 - - - -
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12

Profile*

Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

15 Independence Blvd, Warren, NJ, United States, 07059

877 838 6436

https://tevogen.com

Name Title Year Born
Dr. Ryan H. Saadi M.D., M.P.H, M.P.H. Co-Founder, CEO & Chairman NA
Mr. Kirti Desai CFO & Director NA
Mr. Stephen Chen M.B.A. Chief Technical Officer NA
Dr. Neal Flomenberg M.D. Chief Scientific Officer, Global R&D Lead & Chairman of Corporate Board NA
Mr. Mittul Mehta Chief Information Officer & Head of Tevogen.ai NA
Mr. Tapan V. Shah Head of Investor Relations & Corporate Development NA
Mr. Jeffrey Feike M.P.H. Chief Patient Officer, Member of Innovation & Public Health Advisory Council & Director NA
Mr. Sadiq Khan Chief Commercial Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…